Skip to main content
Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD
Keira Smith
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.  
Lung Cancer Awareness Month: A Fellows Forum Panel With Waqas Haque, MD, MPH; Samuel Kareff, MD, MPH; and Matthew Hadfield, DO
Keira Smith
Expert Analysis
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami. 
Creating Educational Opportunities During Fellowship: Board Exam Prep, Live Meetings, and Beyond With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) me...
Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD
Keira Smith
Expert Analysis
At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  
Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN
Keira Smith
Expert Analysis
For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  
Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for Triple-Negative Breast Cancer With Kevin Kalinsky, MD, MS
Lyn Brook
Expert Analysis
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metast...
Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH
Keira Smith
Expert Analysis
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.  
Self-Management Strategies for Peripheral Neuropathy: A Breast Cancer Awareness Month Interview With Connie Visovsky, PhD, RN, ACNP, FAAN
Keira Smith
Expert Analysis
In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management strategy for chemotherapy-induced peripheral neuropathy (CIPN) experienced by patients during breast cancer treatment. Additionally, she gives an update on her presentation from last year's ODACon Breast Cancer Symposium regarding new directions in research for CDK4/6 inhibitors.  
Breast Cancer Awareness Month: Debunking Breast Cancer Myths With Jason Mouabbi, MD
Keira Smith
Expert Analysis
In this interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, provides insightful answers to frequently asked questions and debunks common myths surrounding breast cancer diagnosis, screening, and treatment.  
Embracing Compassion in Health Care: The Power of Being Present With Marcus Engel, MS, CXCP, CSP
Keira Smith
Expert Analysis
In this interview, Marcus Engel, MS, CXCP, CSP, a renowned health care author and speaker, sat down with Oncology Data Advisor to share his personal experiences of receiving compassion in the health care system, its implication for patient care, and ways that medical professionals can embrace compassion and integrate it into their practice.  
Pink Fund: Providing Financial Assistance During Breast Cancer Treatment With Founder Molly MacDonald
Keira Smith
Expert Analysis
For individuals with breast cancer, financial toxicity is a significant and often overwhelming part of the fight. Pink Fund is an organization which provides 90-day non-medical cost-of-living expenses, including housing, transportation, utilities, and insurance costs, for patients undergoing active treatment for breast cancer, enabling them to focus on healing before returning to the workplace. In this interview, Pink Fund's Founder, Molly MacDonald, shares the story of how she founded the organization, resources for both patients who are experiencing financial toxicity and for clinicians seeking to support their patients, and crucial messages for raising awareness of financial toxicity during cancer treatment.  
The Importance of Exercise for Cancer Survivorship With Nagashree Seetharamu, MD, MBBS
Lyn Brook
Expert Analysis
In this interview, Dr. Nagashree Seetharamu, MD, MBBS, a Professor in the Division of Hematology and Medical Oncology in the Department of Medicine at Hofstra Northwell Health, sat down to discuss the vital role that exercise takes in the cancer treatment and recovery process. As well, she shares advice on why an individualized approach to a patien...
Exploring Educational Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield, DO, and Richa Thakur, MD
Keira Smith
Expert Analysis
In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different types of educational opportunities available during fellowship, including podcasts and in-person meetings, and strategies for finding th...
Enfortumab Vedotin Plus Pembrolizumab: Results of the EV-302 Trial With Thomas Powles, MD, MBBS, MRCP
Keira Smith
Expert Analysis
In this interview, Thomas Powles, MD, MBBS, MRCP, Director of the Barts Cancer Center in London, sat down with Oncology Data Advisor to discuss the results of the EV-302 trial, a phase 3, open-label investigation of enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer.   Oncology Data ...
Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Results from IMS 2023 With Madhav Dhodapkar, MD
Keira Smith
Expert Analysis
At the International Myeloma Society (IMS) 2023 Annual Meeting and Exposition, Dr. Madhav Dhodapkar, Director of the Cancer Center at Emory University, presented the results of the LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma. Here, he further delves into the efficacy of linvoseltamab observed in the trial and its projected place in the treatment landscape.  
World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD
Keira Smith
Expert Analysis
In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.  
Twice Weekly, Biweekly, or Somewhere in Between? Updates on Dosing Schedules in Multiple Myeloma With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
In honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.  
The Rise of Immunotherapy: Considerations to Ensure Optimal Management With Matthew Hadfield, DO
Keira Smith
Expert Analysis
In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.  
World Cancer Research Day: How to Get Involved in Research With Waqas Haque, MD, MPH
Keira Smith
Expert Analysis
In honor of World Cancer Research Day, Dr. Waqas Haque, a third-year Internal Medicine Resident at New York University (NYU) and Oncology Data Advisor Fellows Forum member, shares advice for residents and fellows who are interested in becoming involved in oncology research. Dr. Haque offers practical tips for finding a mentor, identifying and exploring a research topic, making time for projects amidst a busy schedule, balancing research with patient care, and much more.  
Finding Your Why: Reflecting on the Passion Behind Oncology Nursing With Lauren Ghazal, PhD, FNP-BC
Keira Smith
Expert Analysis
At the 2023 Oncology Nursing Society (ONS) Bridge Conference, Dr. Lauren Ghazal, Assistant Professor in the School of Nursing at the University of Rochester Medical School and Oncology Data Advisor Editorial Board member, gave the keynote presentation entitled "Finding Your Why." Afterwards, she sat down to share further insights into the presentation, advice for nurses who are reflecting upon their "why" at different stages of their career, and how asking this question will not only help nurses to build fulfilling careers but to also strengthen nursing sustainability on a larger scale.